Fourpath Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Fourpath Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$310K	Hold	5,383	–	–	0.04%	188
2026 Q1	$326K	Hold	5,383	–	–	0.05%	179
2025 Q4	$290K	Hold	5,383	–	–	0.04%	183
2025 Q3	$243K	Sell	5,383 -575	-10%	-$26.9K	0.03%	199
2025 Q2	$276K	Sell	5,958 -16,373	-73%	-$804K	0.04%	194
2025 Q1	$1.36M	Sell	22,331 -2,218	-9%	-$129K	0.24%	78
2024 Q4	$1.39M	Buy	24,549 +466	+2%	+$26K	0.26%	78
2024 Q3	$1.25M	Buy	24,083 +8,457	+54%	+$397K	0.23%	83
2024 Q2	$649K	Buy	15,626 +5,219	+50%	+$234K	0.48%	50
2024 Q1	$564K	Buy	+10,407	New	+$530K	0.39%	61
2022 Q4	–	Sell	-4,729	Closed	-$336K	–	120
2022 Q3	$336K	Sell	4,729 -4,633	-49%	-$336K	0.23%	85
2022 Q2	$721K	Sell	9,362 -3,729	-28%	-$284K	0.45%	52
2022 Q1	$956K	Buy	13,091 +5,556	+74%	+$373K	0.38%	44
2021 Q4	$470K	Buy	+7,535	New	+$442K	0.18%	97

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fourpath Capital Management's BMY Position: Q2 2026 in Review

Fourpath Capital Management held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 5,383 shares worth $310K. The position accounts for 0.04% of the portfolio, ranked #188.

Fourpath Capital Management first reported a position in BMY in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.39M in Q4 2024. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Fourpath Capital Management held 5,383 shares of Bristol-Myers Squibb worth $310K as of Q2 2026.
Fourpath Capital Management left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.04% of Fourpath Capital Management's portfolio in Q2 2026, its #188 holding.
Fourpath Capital Management first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 14 quarters since.
Fourpath Capital Management's Bristol-Myers Squibb position peaked at $1.39M in Q4 2024.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Fourpath Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.